LONGMONT, CO -- (Marketwired) -- 06/27/14 -- MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that further to its press release dated May 27, 2014, the Company's new product "MediStrip Relaxation" dissolvable oral strips are now available for sale at www.GoKush.com.
GoKush.com (www.GoKush.com) is part of a members only collective comprised of verified legal medical marijuana patients in the State of California. The GoKush platform allows same day and overnight delivery of medical marijuana to its registered customer base.
MediJane's MediStrip Relaxation will be offered to GoKush customers at an introductory price of $12.50 for a single cool-mint strip or $87.50 for a package of 7. Each MediStrip Relaxation is individually packaged for freshness and consistency, and contains 25 mg THC, 2 mg CBD, and 2 mg CBN derived from high-quality Cold Ethanol extracted cannabis oil.
"We are excited to finally be ready to offer GoKush patients this exciting, unique, and convenient new product from MediJane," stated GoKush founder Mac Bagley. "We are very pleased that MediJane has been able to devise and formulate such innovative delivery systems for the medical marijuana space, so I encourage our existing and potential new customers to visit www.GoKush.com to try this new product at an introductory price before it's gone."
Lewis "Spike" Humer, Chairman of MediJane Holdings, concluded, "This delivery further solidifies our relationship with GoKush and opens the door for potential new MediJane products to be provided through GoKush. This also represents a continuation of our overall growth as a company and demonstrations our commitment to becoming and remaining the premier medical cannabis company in the market."
For additional information regarding MediStrip Relaxation, visit www.mjmd.net/medistrip-relaxation/
About MediJane Holdings Inc. (MJMD)
MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, oral strips, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals (www.phoenixbiopharmaceuticals.com). With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's products, including the innovative non-drowsy "Daytime Pain plus CBD" oral capsule, the Canna-Mist cannabinoid spray, and the MediStrip Relaxation oral strips, have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These smokeless alternatives provide accurate dosages and are part of MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America. Any and all medically oriented statements have not been evaluated by the Food and Drug Administration.
For more information, visit www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.